ArticleACS omega2025
Ultra-sensitive Quantification of Mid-regional Proadrenomedullin in Human Plasma Using Micro-liquid Chromatography Coupled to Quadrupole Time-of-Flight Mass Spectrometry.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mid-regional proadrenomedullin (MR-proADM) has been suggested to be a powerful biomarker for the onset, progression, and mortality of various diseases. To achieve sensitive quantification of MR-proADM without cross-reactivity, we established micro-liquid chromatography coupled to the quadrupole time-of-flight mass spectrometry (μLC-QTOF/MS) method using IonKey technology. 100 μL of plasma sample was pretreated by protein precipitation followed by solid-phase extraction. Using the established μLC-QTOF/MS method, plasma MR-proADM concentrations were measured in 198 individuals of the Japanese general population, 13 patients with chronic kidney disease (CKD) stage G3b-G4 (nondialysis), and 12 patients with CKD stage G5 (dialysis). The novel assay fulfilled the requirements of the US Food and Drug Administration guidance for bioanalytical method validation, with a lower limit of quantification of 0.05 ng/mL. Recovery rates from human plasma and matrix effects were 89.6-114.2% and 95.3-111.7%, respectively. Median plasma MR-proADM concentrations were 0.48, 1.16, and 2.75 ng/mL in general population, CKD stage G3b-G4, and CKD stage G5, respectively (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.